Outsourced Pharma Services: Focus on Clinical Services

As the market stands today, if you ask a health care investor which areas they are targeting, you’ll likely hear behavioral health, physician practices, technology enabled health care, and outsourced pharma services.

Given the dynamic interplay of health care economic policy, government regulations, reimbursement, therapeutic advances, and technology, it likely comes as no surprise that in health care services M&A, sectors fall in and out of favor. As the market stands today, if you ask a health care investor which areas they are targeting, you’ll likely hear one or more of the following: behavioral health, physician practices, all manner of technology enabled health care, and, for the purposes of this report, outsourced pharma services.

First off, what are outsourced pharma services?

Not such a simple question, as there are a variety of ways industry insiders define and delineate this broad category.

For simplicity, we break the market down into three major areas — Clinical Services, Supply Chain, and Commercialization.

Clinical Services

In the clinical services bucket, we have providers focused on pre-clinical and clinical pharma development such as contract research organizations (CROs) – large scale firms that manage and coordinate activities across the drug development spectrum, clinical trials sites and networks, and functional service providers (FSPs), that among other areas, offer specialized expertise such as clinical monitoring, patient recruitment, data management and analysis, clinical safety, and quality assurance. These companies are essential partners that support moving products through the various regulatory stages with the ultimate goal of gaining approval and market authorization.

Supply Chain

Under supply chain, we have all the functions involved in getting drug substances and finished products from development through delivery, including materials sourcing and procurement, production planning and inventory management – often the domain of contract development and manufacturing organizations (CDMOs), packaging, labeling and serialization, and logistics and distribution.

Commercialization Services

Under commercialization, services include patient and health care professional engagement, market access and payer strategy development – including interfacing with CMS and developing formularies, health economics and outcomes research (HEOR), patient hubs, medical affairs and communication, adverse event monitoring, and outcome studies.

Why Buyers Have Heightened Interest In Outsourced Pharma Services

To put it simply, ushering a drug from discovery to commercialization is a massive undertaking. The steps involved are extraordinarily complex, require highly specialized niche expertise, are loaded with data that must be monitored, cleaned, and analyzed in real time, and can be global in scope. Managing that kind of operation in-house is expensive and slow. Outsourcing lets pharma companies scale quickly and access deep expertise without building it themselves, changing an otherwise fixed cost to one that is variable. Moreover, outsourcing clinical services, notably the various aspects of conducting clinical trials, also provides the external objectivity and validation that would otherwise be questioned if performed by pharma. What’s more, as we detail below, the market is extremely fragmented (which allows for consolidation), sizeable, and growing.

No surprise, then, that private equity has noticed, pouring money into the space and driving M&A activity.

In this market report, we focus on Clinical Services.

The Market

According to a summary report on the clinical trials ecosystem produced by Market and Markets, “the global Clinical Trial Services market, valued at US$60.76 billion in 2024, stood at US$66.59 billion in 2025 and is projected to advance at a resilient CAGR of 8.9% from 2025 to 2030, culminating in a forecasted valuation of US$101.86 billion by the end of the period.” ¹

Below are just a few of the primary growth drivers:

Sustained, and growing need, for drug therapies in the areas of mental health and psychiatrics – notably psychedelics, rare diseases, pediatrics, GLP-1s, and the omnipresent oncologics

Looming “patent cliffs” that, among other initiatives, will spur research and development

Goals to increase diversification in trials across age, sex, ethnicity, and race

Technology enabled initiatives to improve patient access through decentralized clinical trials

One other observation.

Under the Inflation Reduction Act of 2022, CMS can negotiate prices for certain high-cost, single-source drugs once they’ve been on the market for a set number of years. The clock starts the day the drug is first approved by the FDA — not when it launches for a second indication or formulation. After that point, the law defines a specific number of years before the drug becomes eligible for Medicare price negotiation. So, to maximize their returns before the “exclusive window” ends, pharma has tremendous incentives to identify every potential indication for an individual drug as quickly as possible. This, in turn, is likely to spur more clinical trials earlier in the drug development process.

¹Markets and Markets: https://www.marketsandmarkets.com/Market-Reports/clinical-trials-market-405.html

Valuation Considerations

Clinical Differentiators

In discovery, preclinical, and clinical outsourcing, the best partners distinguish themselves not just by size or scale, but by how they integrate science, technology, and collaboration into every project. Their success tends to cluster around four key traits: expertise, execution, innovation, and partnership.

Expertise. Top-tier CROs and trial sites go deep into their therapeutic focus — oncology, CNS, or rare diseases and stay fluent in the evolving regulatory and technical landscape. They connect early-stage discovery insights to downstream protocol design, reducing trial risk and cost.

Execution. The best firms deliver on time, every time. They run highly controlled operations with proven SOPs, validated systems, and scalable infrastructure that can flex based on a client’s needs and objectives.

Technology and Data. High performers utilize digital platforms that make data capture, monitoring, and analytics seamless. They are evaluating and developing AI strategies to predict enrollment bottlenecks, automate reporting, and give sponsors real-time visibility into trial progress.

Partnership. Another differentiator is the extent to which firms work as an extension of their partners. Whether that be with the sponsor team directly, or with CROs that manage and coordinate activities, high performers communicate clearly, tailor their processes, and maintain continuity in leadership and staff across projects. Their culture is as collaborative as it is disciplined. Firms that display these characteristics will rise to the top of buyers’ wish lists.

Financial and Operational Differentiators

Growth rate and pipeline: No surprise that firms with higher growth and stronger pipelines command higher multiples. But there is some nuance here. Given the discrete project nature of clinical development and trials, unless a firm is conducting a large number of trials at various stages in their life cycles, revenues – and earnings – can be extremely “lumpy.” This makes the calculation of historic trailing and projected go-forward financial performance extremely hard to determine – a factor buyers consider by either risk adjusting valuation multiples, or the earnings being multiplied, downward. So, the best-case scenario? Firms with smooth revenue streams that are trending upward and to the right.

Therapeutic diversity. Niche expertise can be extremely attractive (see below). The downside, however, is that any number of variables can upend a particular drug development focus. For example, companies that developed expertise in pain management likely saw fewer opportunities as a wave of litigation, DEA scrutiny, and tighter FDA guidance effectively froze new opioid-related development programs. The upshot? Diversification that reduces risk increases value.

Specialization. The above notwithstanding, firms that have niche expertise in attractive therapeutic domains have competitive advantages that not only create barriers to entry for competitors but also enable them to command higher pricing – both attractive attributes for buyers. Moreover, they can be extremely valuable to consolidators seeking to create a diversified portfolio of offerings per the above.

Size and scale: Akin to therapeutic diversity, larger firms, perhaps with a global footprint, that in addition to broad service offerings have fully developed clinical, operational, and marketing infrastructures are inherently less risky than smaller, owner/physician/investigator operated sites or providers, and therefore command higher valuations. It’s not that the smaller firms aren’t attractive – in fact, they are. They simply aren’t at the highest end of the valuation continuum.

Client stickiness: The “stickier” the relationship between a provider and a sponsor or other contractor, i.e. the more difficult and inefficient to engage with a different outsourcer, the greater the value.

For example, once a CRO runs a trial for a sponsor, and becomes familiar with the drug, protocol, data systems, and regulatory expectations, it becomes riskier and more inefficient for the sponsor to switch mid-trial or between phases.

Similarly, at the site level, sponsors and CROs prefer continuity in site relationships — investigators who already understand trial protocols, recruiting pipelines, and patient populations.

For FSPs, the vendor’s employees (the FSP’s specialists) often work directly in the sponsor’s systems — the sponsor’s databases, templates, SOPs, and project tools. They may report day-to-day to sponsor managers or liaisons, even though they’re employed by the FSP and often adopt the sponsor’s internal processes, attend their meetings, and function almost as in-house staff. All of which makes it extremely difficult to switch to a different vendor.

Valuation Indicators

For context, it’s perhaps helpful to see what the range of multiples are in the other health care services sectors we cover. At the lower end of the range is home medical equipment providers that currently trade at 5.0 -7.0 x EBITDA less Capex.2 At the higher end of the range are behavioral health service providers which command multiples of 8.0 to 10.0 x, or more. Of course, it goes without saying that the size and individual attributes of a given provider can generate multiples well outside these ranges – both higher, and lower.

So, what do we see in outsourced pharma services?

Not surprisingly, it differs across the segments within the space. One thing noteworthy is that almost by definition, large clinical trials networks, CROs, and CDMOs not only have risk-return fundamentals that place them at the higher end of the valuation range, but they also tend to be the firms with the highest revenues and earnings. Therefore, their valuation indicators are inclusive of a “size premium” which, in and of itself, can add another 3.0 – 5.0 times EBITDA.

Below is an illustration of the ranges of value multiples we see across the outsourced pharma services continuum. As suggested above, these are rough ranges of value that can move up or down based upon company specifics.

²The subtraction of Capex from EBITDA is significant, as the resulting imputed EBITDA multiple can easily fall below 5.0. For example, if EBITDA is $10M and Capex is $5.0M, the EBITDA less Capex that is subject to the multiple range quoted above is $5.0M. At a 7.0 multiple, the value would be $35M. But as a function of EBITDA, the multiple falls from 7.0 to 3.5.

Outlook

While the post-COVID slowdown on new drug development, reduced access to venture capital funding, and price controls courtesy of the Inflation Reduction Act have, among other developments, become part of the M&A calculus, for all the reasons delineated above, outsourced pharmacy remains innately attractive.

As we have seen in virtually all the sectors we cover, it has been the macroeconomic environment that has had the most impact on deal flow.

The Macroeconomic Environment

Following COVID, from mid-2022 through 2024, the macroeconomic environment was characterized by (a) economic instability, (b) staffing challenges, (c) the fallout from unprecedentedly high M&A volume and valuations in 2021, (d) inflation, and (e) the Fed’s response to it by raising interest rates. As a result, buyers understandably pulled back globally, and across all industries. But over that 30-month slowdown, unspent private equity capital and acquisition demand naturally began to build. So, it’s been a standoff between less than favorable macroeconomic conditions and buyer demand. Thus far in 2025, however, it appears that demand has begun to overcome the macroeconomics, as deal volume shows real signs of recovery. What’s more, the Fed lowered interest rates in September and October, bringing the range to 3.75 – 4.0%, the lowest in three years (and down from a peak of 5.4% which was in place for much of 2024). And with President Trump getting the opportunity in May to replace the current Fed Chair, Jerome Powell, with whom he’s had a very public dispute regarding lowering interest rates, we may see additional cuts next year.

As such, there’s good reason to believe that the uptick in deal making in 2025 will continue in 2026, which, when combined with the tailwinds described in this report, should boost opportunities for outsourced pharma companies.